Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Laslop

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
ESMO Open|December 5, 2019
Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countriesNils Wilking, Anna Bucsics, Lidlija Kandolf Sekulovic, et al.
Investigative Ophthalmology & Visual Science|January 27, 2005
Secretoneurin in the peripheral ocular innervationJosef Troger, Alfred Doblinger, Johannes Leierer, et al.
Drugs|April 1, 2025
The Tailored Biosimilar Approach: Expectations and RequirementsElena Guillen, Sean Barry, Nils Jost, et al.
Investigative Ophthalmology & Visual Science|December 30, 2004
Neurokinin a is a main constituent of sensory neurons innervating the anterior segment of the eyeEduard Schmid, Johannes Leierer, Alfred Doblinger, et al.
Bone|March 4, 2008
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosisRené Rizzoli, Nansa Burlet, David Cahall, et al.
Journal of the American Geriatrics Society|May 17, 2024
Medicines for an aging population: The EMA perspective and policiesFrancesca Cerreta, Ewa Balkowiec Iskra, Amelia Cupelli, et al.
Drugs & Aging|February 22, 2015
Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritisOlivier Bruyère, Cyrus Cooper, Nigel Arden, et al.
Osteoarthritis and Cartilage|March 17, 2004
Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritisEric Abadie, Dominique Ethgen, Bernard Avouac, et al.
Ageing Research Reviews|August 23, 2019
Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO)Emmanuel Biver, Francis Berenbaum, Ana M Valdes, et al.
Calcified Tissue International|January 12, 2023
Biochemical Markers of Musculoskeletal Health and Aging to be Assessed in Clinical Trials of Drugs Aiming at the Treatment of Sarcopenia: Consensus Paper from an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d'Expérimentation en Santé (CARES SPRL), Under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and AgingAurélie Ladang, Charlotte Beaudart, Jean-Yves Reginster, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
ESMO Open|December 5, 2019
Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countriesNils Wilking, Anna Bucsics, Lidlija Kandolf Sekulovic, et al.
Investigative Ophthalmology & Visual Science|January 27, 2005
Secretoneurin in the peripheral ocular innervationJosef Troger, Alfred Doblinger, Johannes Leierer, et al.
Drugs|April 1, 2025
The Tailored Biosimilar Approach: Expectations and RequirementsElena Guillen, Sean Barry, Nils Jost, et al.
Investigative Ophthalmology & Visual Science|December 30, 2004
Neurokinin a is a main constituent of sensory neurons innervating the anterior segment of the eyeEduard Schmid, Johannes Leierer, Alfred Doblinger, et al.
Bone|March 4, 2008
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosisRené Rizzoli, Nansa Burlet, David Cahall, et al.
Journal of the American Geriatrics Society|May 17, 2024
Medicines for an aging population: The EMA perspective and policiesFrancesca Cerreta, Ewa Balkowiec Iskra, Amelia Cupelli, et al.
Drugs & Aging|February 22, 2015
Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritisOlivier Bruyère, Cyrus Cooper, Nigel Arden, et al.
Osteoarthritis and Cartilage|March 17, 2004
Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritisEric Abadie, Dominique Ethgen, Bernard Avouac, et al.
Ageing Research Reviews|August 23, 2019
Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO)Emmanuel Biver, Francis Berenbaum, Ana M Valdes, et al.
Calcified Tissue International|January 12, 2023
Biochemical Markers of Musculoskeletal Health and Aging to be Assessed in Clinical Trials of Drugs Aiming at the Treatment of Sarcopenia: Consensus Paper from an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d'Expérimentation en Santé (CARES SPRL), Under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and AgingAurélie Ladang, Charlotte Beaudart, Jean-Yves Reginster, et al.
Pageof 5